BSD Medical Hyperthermia System Purchased by Major East Coast U.S. Academic Medical Center

  BSD Medical Hyperthermia System Purchased by Major East Coast U.S. Academic
  Medical Center

Business Wire

SALT LAKE CITY -- January 31, 2013

BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) announced
today that a major East Coast academic medical center (the “Center”) has
purchased a BSD-500 Hyperthermia System (BSD-500). The Center is launching an
extensive new hyperthermia program to capitalize on the advantages provided by
hyperthermia treatment.

“This latest sale is an indicator of the most recent success of hyperthermia
in key academic medical centers for the treatment of certain recurrent cancer
patients,” said Harold Wolcott, BSD’s President. BSD’s website
www.BSDMedical.com includes a list of all U.S. based hyperthermia treatment
centers.

About the BSD-500 Hyperthermia System

The BSD-500 Hyperthermia System is used to deliver therapeutic heating
(hyperthermia) using either non-invasive (external) hyperthermia, which is
delivered using antennas placed over the tumor, or interstitial hyperthermia,
which is delivered using antennas that are inserted into the tumor, or a
combination of both. The BSD-500 has received U.S. Food and Drug
Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in
conjunction with radiation therapy to treat certain tumors.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
Bill Barth, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930
 
Press spacebar to pause and continue. Press esc to stop.